ViroCarb Inc. announces funding to develop a novel oral anti-COVID 19 treatment
ViroCarb Inc.
TORONTO, ONTARIO, CANADA, March 15, 2022 /EINPresswire.com/ -- ViroCarb Inc. is pleased to announce that it is receiving advisory services and funding of up to $160,500 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) supporting a research and development project to advance the Company's preclinical development of an innovative oral treatment for COVID-19.
Unlike drugs that target viral components unique to a single virus, ViroCarb’s small molecule drug platform disrupts viral RNA processing and blocks the replication of multiple viral families. This MOA translates into a broad-spectrum host cell resistance to known and potentially new emerging viruses and endows a low propensity for drug resistance.
“We are very grateful to NRC IRAP for their support in advancing our ongoing preclinical research program. Our focus is on developing a novel broad-spectrum oral treatment, with a reduced propensity for drug resistance that limits current virus-targeted approaches,” said Bharat Tewarie, MD, MBA, ViroCarb’s CEO. “Our immediate goal is to develop a most needed effective oral treatment of infections caused by SARS-COV-2 and future emerging variants.”
About ViroCarb Inc. (www.virocarb.com)
ViroCarb Inc. is an antiviral company with a paradigm shift drug platform that provides broad-spectrum protection against current and newly emerging pathogenic viruses to overcome the clinical challenges of viral infection.
For more information contact:
Mario Huesca, Ph.D. President & Chief Operating Officer
ViroCarb Inc
+1 647-772-9437
mailto:mario.huesca@virocarb.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
